Royalty Pharma 

Yahoo Finance • 2 days ago

Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally

On May 8, 2026, CM Management reported selling its entire 200,000-share stake in Centerra Gold(NYSE:CGAU), an estimated $3.56 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi... Full story

Yahoo Finance • 4 days ago

This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge

On May 8, 2026, CM Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold its entire stake in Preformed Line Products(NASDAQ:PLPC), an estimated $6.39 million trade based on quarterly average pricing.... Full story

Yahoo Finance • 6 days ago

Royalty Pharma plc Q1 2026 Earnings Call Summary

Royalty Pharma plc Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Delivered 13% growth in recurring royalty receipts, driven by a diversified portfolio and the absorption of the Promacta loss of exclusi... Full story

Yahoo Finance • 6 days ago

Royalty Pharma reports Q1 results; raises FY26 outlook

* Royalty Pharma press release [https://seekingalpha.com/pr/20502630-royalty-pharma-reports-first-quarter-2026-results] (RPRX [https://seekingalpha.com/symbol/RPRX]): Q1 Revenue of $631M (+11.1% Y/Y) misses by $243.12M. * Portfolio Rec... Full story

Yahoo Finance • 6 days ago

Royalty Pharma reports first quarter 2026 results

Royalty Pharma plc Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million... Full story

Yahoo Finance • 17 days ago

Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment

Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from adva... Full story

Yahoo Finance • 19 days ago

3 Unpopular Stocks We’re Skeptical Of

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating bus... Full story

Yahoo Finance • 21 days ago

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will hono... Full story

Yahoo Finance • 22 days ago

Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now

Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now. Royalty Pharma Plc (NASDAQ:RPRX) announced on April 17 that its board of directors approved the payment of a dividend for the second quarter o... Full story

Yahoo Finance • 26 days ago

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company wil... Full story

Yahoo Finance • 29 days ago

Royalty Pharma plc (RPRX) Proved Resilience in Q1 by Gaining 25.6%

Patient Capital Management, based in Baltimore, released its first-quarter 2026 investor letter for the “Patient Opportunity Equity Strategy,” available for download here. The strategy’s long-term value approach aims to build wealth over t... Full story

Yahoo Finance • last month

Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal

Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Diversified Dividend Stocks to Buy Right Now.Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal On March 30, Reuters reported that Royalty Pharma entered into a $... Full story

Yahoo Finance • last month

Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Johnson & Johnson (NYSE:JNJ) has entered a $500m R&D co funding agreement with Royalty Pharma to advance JNJ-4804, a first in clas... Full story

Yahoo Finance • last month

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Royalty Pharma plc NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to... Full story

Yahoo Finance • 2 months ago

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?

Royalty Pharma has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 31.5% and now trades at $45.91. This performance may have investors wondering how to approach the situation. Is now... Full story

Yahoo Finance • 2 months ago

Moderna stands as the best performing large-cap healthcare stock YTD

[Heart Health Concept] Eoneren/E+ via Getty Images U.S. large-cap healthcare stocks have delivered modest year-to-date gains in 2026, holding steady into March amid its defensive appeal. Below is a list of the top 10 large-cap healthcare... Full story

Yahoo Finance • 2 months ago

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of... Full story

Yahoo Finance • 2 months ago

How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Royalty Pharma’s updated fair value price target now sits at US$51.56, compared with the previous US$51.00 level. Anal... Full story

Yahoo Finance • 2 months ago

Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule

Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now. On February 11, Royalty Pharma reported a year of robust financial performance in 2025, marked by a 16% increase in total portfolio receipts and an 18% jump in Q4 alo... Full story

Yahoo Finance • 2 months ago

Zymeworks Q4 Earnings Call Highlights

Zymeworks logo Zymeworks Offers Hope for More than Just Long-Term Investors Zymeworks (NASDAQ:ZYME) executives used the company’s fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidat... Full story